((自动化翻译由路透提供,请见免责声明 )) (第2-3段增加了交易细节)
路透10月28日 - 美国制药商艾伯维 周一表示,将以14亿美元现金收购Aliada Therapeutics公司,获得该疗法开发商的阿尔茨海默病候选药物。
Aliada正在开发一种治疗阿尔茨海默病的抗体ALIA-1758,艾伯维称它可能成为一种最佳疗法。
该交易预计将于今年年底完成。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.